Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
The Settlement In a Tuesday statement, HHS OCR says its settlement with Banner Health came after two complaints.
In the first complaint, a patient said she requested access to her medical records in December 2017 but did not receive the records until May 2018. The second complaint alleged that another individual requested access to an electronic copy of his records in September 2019, but the records were not sent until February 2020.
“This first resolution of the year signals that our right of access initiative is still going strong and that providers of all sizes need to respect the right of patients to have timely access to their medical records,” said Roger Severino, OCR director.
MedCity News
At CES, experts say transparency key to ensuring AI tools work as intended
AI tools increasingly occupy a regulatory gray area in healthcare. For clinicians to assess whether they are trustworthy, they need transparency on how they work, said panelists at CES.
Shares0
A host of AI tools have been quickly developed to respond to the Covid-19 pandemic, from algorithms to screen lung x-rays for signs of Covid-19, to triage tools to predict which patients will become critically ill. But how do we know they are working as planned?
Transparency in how these tools are developed and their intended use is critical, experts said at a virtual panel at CES.
Saturday, January 9, 2021
The U.S. Food and Drug Administration had a busy 2020, as detailed in earlier blog posts. This blog post explores politics and a few policy activities we’ll be keeping an eye on in 2021 and how they might impact medical product manufacturers, particularly now that we know the U.S. Senate will be controlled, like the U.S. House of Representatives and the White House, by Democrats.
Politics
Chairmanship of the powerful House Energy & Commerce Committee, which has jurisdiction over FDA, remains with Rep. Frank Pallone of New Jersey while Senator Patty Murray of Washington is in line to helm the Senate Health, Education, Labor, and Pension (HELP) Committee. While President-elect Joe Biden has announced his picks for Secretary of Health and Human Services (California Attorney General Xavier Beccera) and Director of the Centers for Disease Control and Prevention (Rochelle Walensky, chief of the Infectious Diseases at Massachusetts General Hospital
To embed, copy and paste the code into your website or blog:
Passed by Congress Dec. 21, 2020, and signed by President Donald Trump Dec. 27, 2020, the $1.4 trillion omnibus Consolidated Appropriations Act includes numerous provisions that directly impact Medicare and Medicaid beneficiaries. To assist the healthcare industry in understanding the policies included in the provisions summarized below, this alert includes the House bill numbers introduced during the 116th Congress, which concluded at year’s end.
Medicare Provisions
Extends coverage of immunosuppressive drugs for kidney transplant patients and includes other renal dialysis provisions (i.e., H.R. 5534)
Provides Medicare coverage for immunosuppressive drugs to post-kidney transplant individuals whose coverage under Medicare Part A otherwise ends post-transplant, and whose drugs are not covered by other insurance.